Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Samenvatting: Agenus kondigt een overtekende onderhandse plaatsing aan van maximaal 340 miljoen dollar ter ondersteuning van de ROBBIN-registratiestudie naar neoadjuvante BOT+BAL bij MSS-darmkanker

Wednesday, July 15, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced a private placement agreement aiming to raise up to $340 million to support its ROBBIN registration study for neoadjuvant BOT+BAL in MSS colorectal cancer. The initial gross proceeds are approximately $85 million, with an additional $255 million possible through the full exercise of purchase warrants. This funding is expected to bolster Agenus's capabilities in immuno-oncology.
Price reaction · baseline $5.015 (2026-07-15T14:57:00.000Z) · hit during market hours · 4 other AGEN headline(s) in the window, move may be shared
day 0 close · peak
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus secures significant funding to support clinical studies.
  • The placement could enhance resources for innovative cancer treatments.
  • Potential for further financial growth with additional warrant exercises.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+52%
120-day peak, hindsight
Typical move
6.2%
average across 4 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
Botensilimab
Phase 1 · Pancreatic Cancer Metastatic

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een leider op het gebied van innovatie in immuno-oncologie, heeft vandaag bekendgemaakt dat het een overeenkomst voor de aankoop van effecten heeft gesloten voor een onderhandse plaatsing met een bruto-opbrengst van ongeveer 85 miljoen dollar vooraf, vóór aftrek van de kosten van de onderhandse plaatsing, en tot 255 miljoen dollar extra bij volledige uitoefening van de aankoopwarrants. De financiering werd geleid door Commodore Capi

Frequently Asked Questions

What is the purpose of Agenus's private placement?

The private placement aims to raise funds for the ROBBIN registration study in MSS colorectal cancer.

How much funding is Agenus looking to secure?

Agenus is seeking up to $340 million through the private placement.

What are the initial proceeds from the placement?

The initial gross proceeds from the placement are approximately $85 million.

What additional funds can Agenus raise through warrants?

Agenus can raise an additional $255 million through the full exercise of purchase warrants.

ShareAdd on Google
Tags: AGEN Viatris Investor Conferences Healthcare Agenus MSS colorectal cancer immuno-oncology private placement ROBBIN study
Last updated: Jul 15, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~1 mo
High dilution risk
Lead asset
BotensilimabPhase 1
Pancreatic Cancer Metastatic →

Catalyst track record

+52%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →